Validation Data Gallery

  • 1X10^6 HEK TIGIT transient transfected cells (red) and HEK parental cells were surface stained with 0.25 µg FITC Plus conjugated-TIGIT VHH (FITC-tgt). Cells were not fixed.

    1X10^6 HEK TIGIT transient transfected cells (red) and HEK parental cells were surface stained with 0.25 µg FITC Plus conjugated-TIGIT VHH (FITC-tgt). Cells were not fixed.

  • Live HeLa cells transfected with human TIGIT were immunostained with FITC Plus conjugated-TIGIT VHH (FITC-tgt,1:1000, green). Cells were fixed and nuclei were stained with DAPI (blue). Epifluorescence images were acquired with 20x objective and post-processed. 
Note: Immunostaining with FITC-tgt can also be performed after formaldehyde fixation of the cells.

    Live HeLa cells transfected with human TIGIT were immunostained with FITC Plus conjugated-TIGIT VHH (FITC-tgt,1:1000, green). Cells were fixed and nuclei were stained with DAPI (blue). Epifluorescence images were acquired with 20x objective and post-processed.  Note: Immunostaining with FITC-tgt can also be performed after formaldehyde fixation of the cells.

  • Left: 1x10^6 human PBMCs were surface stained with 1ug FITC Plus conjugated TIGIT VHH (FITC-tgt) and CL405 CD3 (CL405-65151). Right: 1x10^6 human PBMCs were surface stained with 1ug FITC Plus conjugated TIGIT VHH (FITC-tgt) (red) or unstained (blue). Cells were not fixed. Lymphocytes were gated.

    Left: 1x10^6 human PBMCs were surface stained with 1ug FITC Plus conjugated TIGIT VHH (FITC-tgt) and CL405 CD3 (CL405-65151). Right: 1x10^6 human PBMCs were surface stained with 1ug FITC Plus conjugated TIGIT VHH (FITC-tgt) (red) or unstained (blue). Cells were not fixed. Lymphocytes were gated.

ChromoTek FITC Plus-conjugated TIGIT VHH

FITC-tgt targets TIGIT in FC and IF applications and shows reactivity with Human samples.
Cat No. FITC-tgt

Host/Type

Alpaca VHH

Reactivity

Human

Applications

FC, IF

Conjugate

FITC Plus

TIGIT-Nanobody, TIGIT-single domain antibody (sdAb), DKFZp667A205; FLJ39873; VSIG9; VSTM3

Size/Concentration: 

-/ -


ご購入について

国内販売は「コスモ・バイオ株式会社」を通じて行っております。お見積り・ご注文はお近くの販売代理店へご連絡ください。


国内在庫・納期について

約2万点のプロテインテック製品をコスモバイオ社物流センター(国内)に在庫しています。国内在庫の有無はコスモバイオ社ホームページの「品番検索」でカタログ番号を検索して確認できます。


保証・サポートについて

テクニカルサポートまたはご購入後1年間の交換/補填対応を承ります。詳細はこちらをご覧ください。


Product Information

FITC-tgt targets TIGIT in FC and IF applications and shows reactivity with Human samples.

ApplicationsFC, IF
ReactivityHuman
ConjugateFITC Plus
Type Nanobody
ClassRecombinant
HostAlpaca
AffinityPicomolar range, below the assay limit (biolayer interferometry)
Molecular Weight14.346 kDa
FormLiquid
Excitation/Emission Maxima Wavelengths495 nm / 524 nm
RRIDAB_3101927
Storage Buffer500 mM NaCl, 10 mM HEPES pH 7.0, 5 mM EDTA, 0.09% sodium azide
Storage ConditionStore at -20°C; Shipped at ambient temperature.
BackgroundTIGIT (T-cell immunoreceptor with Ig and ITIM domains), also known as VSIG9 or VSTM3, is an immune receptor expressed on T cells, including Treg and memory subsets, as well as on NK cells (PMID: 19011627). It contains an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT binds to poliovirus receptor (PVR, also called CD155) with high affinity, and also to PVRL2 (CD112) with lower affinity. The interaction of TIGIT with PVR on dendritic cells increases the secretion of IL-10 and decreases the secretion of proinflammatory cytokine and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells. TIGIT can inhibit NK cytotoxicity directly through its ITIM (PMID: 19815499).